Kindeva, a global CDMO, and Rocket Science Health (RSH), a Canadian technology healthcare company, are looking to find partners to develop a new intranasal delivery platform. 

The non-exclusive agreement will see Kindeva and RSH identify partners for the development of the ‘RSH Olfactory Delivery Device,’ a dual nostril intranasal platform used for precisely targeting specific regions of the nasal cavity. 

The device can deposit most of a drug dose into the Olfactory Clefts. Olfactory Clefts are a desirable target for drug deposition and, historically, a difficult location to reach due to the complex human nasal anatomy. 

Early research suggests the device has the potential to achieve high deposition by ejecting a laminar stream, as compared to conventional intranasal treatments, which eject a plume spray or mist. Furthermore, the RSH technology overcomes complex nasal anatomy through the device’s proprietary dispensing tips that extend past the nasal valve to an optimal vantage point. 

The RSH technology also has a high attention to human factors to ensure the device is accessible, comfortable, and easy to use correctly for accurate dosing, especially among cognitively and or physically impaired patients, and for self-administration.

Kenneth Irving, Rocket Science Health’s Founder and CEO, said, “Knowing subregions of the nasal cavity provide access to different organ systems, most notably the CNS via the Olfactory Clefts, we redesigned the fluidics and user experience to enable precise, targeted delivery. Now, we are ready to bring this technology into clinical trials for advancing dose-dependent medicine.”